Drugs / CG-102-12C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07039201 | Jun 2025 → Mar 2027 expected | hepatocellular carcinoma | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG-102-12C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07039201 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor Autologous T-cell” NCT07039201 ↗ |